Intel stock extends gains after report of possible U.S. government stake
Inspire Medical Systems Inc (NYSE:INSP) stock reached a new 52-week low, touching 124.42 USD. According to InvestingPro analysis, the stock appears undervalued at current levels, with analysts setting price targets ranging from $149 to $270. This milestone reflects a challenging year for the company, as its stock price has decreased by 13.82% over the past 12 months. Despite the market’s reaction, the company maintains strong fundamentals with an impressive 84.65% gross margin and 27.11% revenue growth in the last twelve months. The decline underscores the hurdles the company has faced in maintaining investor confidence amid broader market fluctuations. Despite the downturn, Inspire Medical (TASE:BLWV) Systems continues to focus on its innovative solutions in the medical technology sector, aiming to regain momentum and investor trust. The company’s financial health score rates as "GREAT" on InvestingPro, which offers 13 additional key insights about the company’s potential in its comprehensive Pro Research Report.
In other recent news, Inspire Medical Systems has reported impressive financial results for the first quarter of 2025, with earnings per share (EPS) surpassing expectations by $0.35 and achieving a 23% year-over-year revenue growth to $201.3 million. Despite this strong performance, the company has opted to maintain its full-year sales guidance, anticipating a transitional period in the second quarter due to the upcoming launch of its Inspire V product. RBC Capital Markets has maintained an Outperform rating with a $215 price target, reflecting confidence in the company’s growth trajectory. Similarly, KeyBanc Capital Markets reiterated its Overweight rating and $216 price target, noting the progress in launching the Inspire V product. Stifel analysts, however, have maintained a Hold rating with a $175 price target, citing concerns about the unchanged full-year revenue guidance and lower-than-expected second-quarter revenue projections of $210-220 million. The lower guidance is attributed to some physicians postponing procedures and centers managing existing inventory ahead of the new product launch. Despite these challenges, the company remains focused on training surgeons and integrating its SleepSync digital platform for the Inspire V procedures.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.